Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform

被引:59
作者
Brena, RM
Auer, H
Kornacker, K
Hackanson, B
Raval, A
Byrd, JC
Plass, C
机构
[1] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA
[2] Columbus Childrens Res Inst, Columbus, OH USA
[3] Ohio State Univ, Div Sensory Biophys, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Med, Columbus, OH 43210 USA
[5] Ohio State Univ, Ctr Comprehens Canc, Div Hematol Oncol, Columbus, OH 43210 USA
[6] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Hematol Oncol, Columbus, OH 43210 USA
[7] Univ Freiburg, Med Ctr, Dept Hematol, D-7800 Freiburg, Germany
关键词
D O I
10.1093/nar/gnj017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DNA methylation is the best-studied epigenetic modification and describes the conversion of cytosine to 5-methylcytosine. The importance of this phenomenon is that aberrant promoter hypermethylation is a common occurrence in cancer and is frequently associated with gene silencing. Various techniques are currently available for the analysis of DNA methylation. However, accurate and reproducible quantification of DNA methylation remains challenging. In this report, we describe Bio-COBRA (combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform), as a novel approach to quantitative DNA methylation analysis. The combination of a well-established method, COBRA, which interrogates DNA methylation via the restriction enzyme analysis of PCR-amplified bisulfite treated DNAs, with the Bioanalyzer platform allows for the rapid and quantitative assessment of DNA methylation patterns in large sample sets. The sensitivity and reproducibility of Bio-COBRA make it a valuable tool for the analysis of DNA methylation in clinical samples, which could aid in the development of diagnostic and prognostic parameters with respect to disease detection and management.
引用
收藏
页数:8
相关论文
共 39 条
[1]   Chipping away at the chip bias: RNA degradation in microarray analysis [J].
Auer, H ;
Lyianarachchi, S ;
Newsom, D ;
Klisovic, MI ;
Marcucci, U ;
Kornacker, K .
NATURE GENETICS, 2003, 35 (04) :292-293
[2]   Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy [J].
Bastian, PJ ;
Palapattu, GS ;
Lin, XH ;
Yegnasubramanian, S ;
Mangold, LA ;
Trock, B ;
Eisenberger, MA ;
Partin, AW ;
Nelson, WG .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4037-4043
[3]  
Baylin SB, 1998, ADV CANCER RES, V72, P141
[4]   Bisulfite conversion of genomic DNA for methylation analysis: protocol simplification with higher recovery applicable to limited samples and increased throughput [J].
Boyd, VL ;
Zon, G .
ANALYTICAL BIOCHEMISTRY, 2004, 326 (02) :278-280
[5]  
Brock MV, 2003, CLIN CANCER RES, V9, P2912
[6]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107
[7]   CPNPG METHYLATION IN MAMMALIAN-CELLS [J].
CLARK, SJ ;
HARRISON, J ;
FROMMER, M .
NATURE GENETICS, 1995, 10 (01) :20-27
[8]  
CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
[9]   Sensitive and quantitative universal Pyrosequencing™ methylation analysis of CpG sites [J].
Colella, S ;
Shen, L ;
Baggerly, KA ;
Issa, JPJ ;
Krahe, R .
BIOTECHNIQUES, 2003, 35 (01) :146-+
[10]   Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results [J].
Crocitto, LE ;
Korns, D ;
Kretzner, L ;
Shevchuk, T ;
Blair, SL ;
Wilson, TG ;
Ramin, SA ;
Kawachi, MH ;
Smith, SS .
UROLOGY, 2004, 64 (04) :821-825